KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Amortization of Deferred Charges (2017 - 2025)

Emergent BioSolutions (EBS) has 9 years of Amortization of Deferred Charges data on record, last reported at $2.6 million in Q4 2025.

  • For Q4 2025, Amortization of Deferred Charges rose 18.18% year-over-year to $2.6 million; the TTM value through Dec 2025 reached $9.8 million, up 32.43%, while the annual FY2025 figure was $9.8 million, 32.43% up from the prior year.
  • Amortization of Deferred Charges reached $2.6 million in Q4 2025 per EBS's latest filing, up from $2.5 million in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $8.9 million in Q2 2023 and bottomed at -$6.7 million in Q3 2024.
  • Average Amortization of Deferred Charges over 5 years is $2.3 million, with a median of $1.6 million recorded in 2021.
  • Peak YoY movement for Amortization of Deferred Charges: surged 790.0% in 2023, then crashed 217.54% in 2024.
  • A 5-year view of Amortization of Deferred Charges shows it stood at $1.0 million in 2021, then changed by 0.0% to $1.0 million in 2022, then surged by 470.0% to $5.7 million in 2023, then crashed by 61.4% to $2.2 million in 2024, then increased by 18.18% to $2.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Amortization of Deferred Charges were $2.6 million in Q4 2025, $2.5 million in Q3 2025, and $2.4 million in Q2 2025.